Cargando…

Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Podaza, Enrique, Palacios, Florencia, Croci, Diego O., Risnik, Denise, Yan, Xiao J., Almejún, María Belén, Colado, Ana, Elías, Esteban E., Borge, Mercedes, Morande, Pablo E., Bezares, Raimundo, Fernández-Grecco, Horacio, Rabinovich, Gabriel A., Gamberale, Romina, Chiorazzi, Nicholas, Giordano, Mirta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556625/ https://www.ncbi.nlm.nih.gov/pubmed/33054065 http://dx.doi.org/10.3324/haematol.2019.227975

Ejemplares similares

Pulmonary defense and the human cathelicidin hCAP-18/LL-37
por: Fahy, R. J., et al.
Publicado: (2005)

Revisiting the role of interleukin-8 in chronic lymphocytic leukemia
por: Risnik, Denise, et al.
Publicado: (2017)

Enhanced resistance to bacterial and fungal pathogens by overexpression of a human cathelicidin antimicrobial peptide (hCAP18/LL-37) in Chinese cabbage
por: Jung, Yu-Jin, et al.
Publicado: (2011)

Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults
por: Dixon, Brian M, et al.
Publicado: (2012)

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
por: Colado, Ana, et al.
Publicado: (2018)

Cathelicidin hCAP18/LL-37 promotes cell proliferation and suppresses antitumor activity of 1,25(OH)(2)D(3) in hepatocellular carcinoma
por: Zhang, Huidan, et al.
Publicado: (2022)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia
por: Colado, Ana, et al.
Publicado: (2021)

Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer
por: Weber, Günther, et al.
Publicado: (2009)

The Role of Cathelicidin LL-37 in Cancer Development
por: Piktel, Ewelina, et al.
Publicado: (2015)

The human cathelicidin hCAP‐18 in serum of children with haemato‐oncological diseases
por: Jackmann, Natalja, et al.
Publicado: (2022)

Metal-Ion Interactions with Dodecapeptide Fragments of Human Cationic Antimicrobial Protein LL-37 [hCAP(134–170)]
por: Brzeski, Jakub, et al.
Publicado: (2022)

Cathelicidin LL-37 in Health and Diseases of the Oral Cavity
por: Tokajuk, Joanna, et al.
Publicado: (2022)

Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model
por: Simonetti, Oriana, et al.
Publicado: (2021)

Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease
por: Reinholz, Markus, et al.
Publicado: (2012)

Transformation of Human Cathelicidin LL-37 into Selective, Stable, and Potent Antimicrobial Compounds
por: Wang, Guangshun, et al.
Publicado: (2014)

Upregulation of human β-defensin-3 and cathelicidin LL-37 in Kaposi’s sarcoma
por: Fathy, Hanan, et al.
Publicado: (2012)

The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs
por: Kuroda, Kengo, et al.
Publicado: (2015)

Human cathelicidin LL-37 enhance the antibiofilm effect of EGCG on Streptococcus mutans
por: Guo, Yi-jie, et al.
Publicado: (2016)

The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
por: Babikir, Ibrahim H., et al.
Publicado: (2018)

Significance and Diagnostic Role of Antimicrobial Cathelicidins (LL-37) Peptides in Oral Health
por: Khurshid, Zohaib, et al.
Publicado: (2017)

Cathelicidin LL37 Promotes Osteogenic Differentiation in vitro and Bone Regeneration in vivo
por: Li, Lunhao, et al.
Publicado: (2021)

The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus
por: Currie, Silke M., et al.
Publicado: (2013)

Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections
por: Majewski, Karol, et al.
Publicado: (2018)

Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus
por: Moreno-Angarita, Alejandro, et al.
Publicado: (2019)

Regulation of hBD-2, hBD-3, hCAP18/LL37, and Proinflammatory Cytokine Secretion by Human Milk Oligosaccharides in an Organotypic Oral Mucosal Model
por: Gürsoy, Ulvi K., et al.
Publicado: (2021)

Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophages
por: Li, Hsin-Ni, et al.
Publicado: (2009)

The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis
por: Zhang, Ying, et al.
Publicado: (2013)

The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds
por: Duplantier, Allen J., et al.
Publicado: (2013)

Heparan Sulfate Proteoglycan–Involving Immunomodulation by Cathelicidin Antimicrobial Peptides LL-37 and PR-39
por: Kaneider, Nicole C., et al.
Publicado: (2007)

Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats
por: Weng, Jian-Zhen, et al.
Publicado: (2019)

Cathelicidins PMAP-36, LL-37 and CATH-2 are similar peptides with different modes of action
por: Scheenstra, Maaike R., et al.
Publicado: (2019)

Retraction Note: Human cathelicidin LL-37 enhance the antibiofilm effect of EGCG on Streptococcus mutans
por: Guo, Yi-jie, et al.
Publicado: (2017)

Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13
por: Niemirowicz, Katarzyna, et al.
Publicado: (2017)

Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model
por: Nagaoka, Isao, et al.
Publicado: (2020)

Citrullination Alters the Antiviral and Immunomodulatory Activities of the Human Cathelicidin LL-37 During Rhinovirus Infection
por: Casanova, Víctor, et al.
Publicado: (2020)

Sequence determinants in the cathelicidin LL-37 that promote inflammation via presentation of RNA to scavenger receptors
por: Kulkarni, Nikhil N., et al.
Publicado: (2021)

Design, synthesis, and characterization of non-hemolytic antimicrobial peptides related to human cathelicidin LL-37
por: Krishnamoorthy, Rajavenkatesh, et al.
Publicado: (2023)

Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands
por: Morizane, Shin, et al.
Publicado: (2011)

Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37
por: Barlow, Peter G., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_l5ct1d58jsafhb2ur51mpfj2c8